Navigation Links
Potential Brain Cancer Drug for Children May Damage Bones

- Animal Study Raises Caution on Using Signal Transduction Inhibitors in Children -

PHILADELPHIA, March 10 /PRNewswire-USNewswire/ -- A novel drug that fully eliminated brain tumors from mice in a dramatic 2004 study has shown a darker side -- causing permanent bone damage in younger mice. The researcher who conducted both studies says the disappointing new finding raises concerns about using similar drugs to treat children's cancers, at least until there is a more thorough understanding of possible risks.

Tom Curran, Ph.D., a developmental biologist at The Children's Hospital of Philadelphia, led the study, published in the March 2008 issue of the journal Cancer Cell. The drug in question, HhAntag, is a signal transduction inhibitor--an agent that blocks signals along a biological pathway. In mice specially bred for these studies by Curran's research group, HhAntag specifically acts against signals on a pathway leading to medulloblastoma, a type of brain tumor found mostly in children.

Much current cancer research has focused on signal transduction inhibitors (STIs) because of their potential to interrupt specific biological pathways that give rise to cancer. To date, only one STI has been approved by the Food and Drug Administration for use in children. That drug, which acts on different biological pathways than HhAntag does, has not been associated with any developmental defects in children. However, other STIs are currently in pediatric clinical trials.

His team's new findings, says Curran, raise a strong caution. "While it is not clear that the bone defects we observed in mice would also occur in children, and while signal transduction inhibitors may still represent a highly promising approach to treating pediatric cancer, it may be important to perform preclinical testing in young animals before moving ahead to clinical trials," he added. Young animals could provide a model of a drug's potential effects during childhood development.

The drug used by Curran's group acts on the hedgehog (Hh) pathway, which is known to play multiple roles during the development of mammals. Mutations of genes along that pathway lead to different cancers, including medulloblastoma, the most common cancerous brain tumor in children. Because conventional treatment with surgery, radiation and chemotherapy causes serious long-term side effects such as ataxia (a movement disorder) and cognitive impairments, the researchers sought novel, less toxic treatments for medulloblastoma.

In 2001, using genetic engineering, Curran bred mice to develop medulloblastoma. He then treated those mice with HhAntag, which had previously been developed by a biotech company for treating skin cancer in adults. In 2004, while at St. Jude's Children's Research Hospital, Curran reported highly promising results from the mouse studies. At high doses, the drug caused the tumors to shrink and in some cases, disappear entirely. The treated mice also survived much longer than untreated mice, with no serious side effects.

The drug seemed to be an unusually strong candidate for trials in children with the type of medulloblastoma having gene mutations on the Hh pathway--about a third of cases.

However, when Curran's group tested the agent on young mice (10 to 14 days old, in contrast to the adult mice tested previously), they found an unpleasant surprise: serious impairments to developing bones. The mice were smaller, with lower weight and shorter bones than untreated mice, and the effects were not reversible. Even four doses of the drug permanently stunted their growth. "We already knew that the same biological pathway involved in the growth of tumors was also involved in bone development," said Curran, "but we did not expect temporary inhibition to cause an irreversible change in bone growth."

While the current studies were disappointing, said Curran, they do not totally rule out a future role for HhAntag as a treatment for medulloblastoma. "The effects we see in mice may be less dramatic in children, and there may be methods of delivering this drug directly to brain tissue, while avoiding bones. Alternatively, we might discover other drugs that act on the hedgehog pathway but selectively target brain tissue." Another approach, he adds, may be to use HhAntag only in older children who have already completed their growth, or in the admittedly small proportion of medulloblastoma patients who are adults.

"Signal transduction inhibitors such as this drug may still prove beneficial in treating children's cancers, but our findings raise questions about possible adverse effects during childhood development," said Curran.

The National Institutes of Health supported the study. The biotech company Genentech provided supplies of the drug used in the research. Curran's co-authors were Hiromichi Kimura, formerly of St. Jude's Children's Research Hospital; and Jessica M.Y. Ng, of The Children's Hospital of Philadelphia.

About The Children's Hospital of Philadelphia: The Children's Hospital of Philadelphia was founded in 1855 as the nation's first pediatric hospital. Through its long-standing commitment to providing exceptional patient care, training new generations of pediatric healthcare professionals and pioneering major research initiatives, Children's Hospital has fostered many discoveries that have benefited children worldwide. Its pediatric research program is among the largest in the country, ranking third in National Institutes of Health funding. In addition, its unique family-centered care and public service programs have brought the 430-bed hospital recognition as a leading advocate for children and adolescents. For more information, visit

Contact: John Ascenzi

Phone: (267) 426-6055

SOURCE The Children's Hospital of Philadelphia
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. DNA vaccine against multiple sclerosis appears safe, potentially beneficial
2. UCLA study identifies designer estrogen as potential MS drug
3. Office-Based Medical Treatment and Internet Resources Are Potential Solution to Rising Painkiller Misuse Among Teens, Young Adults
4. Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction
5. Potential new approach to treat cognitive impairments in schizophrenia
6. Nosespray vaccine using aloe vera has exciting potential, researcher says
7. Network approach identifies potential breast cancer susceptibility gene
8. Liver fibrosis will be treated by a potential target
9. Researchers study potential health benefits of natural chemicals in muscadine grape seeds
10. Jefferson researchers find stem cells in degenerating spinal discs, potential for repair
11. China Holdings, Inc. Announces 2nd Biomass Renewable Energy Project (Power Capacity: 50 MW); Total Potential: 100 MW in Biomass Energy Pipeline
Post Your Comments:
(Date:10/13/2015)... (PRWEB) , ... October 13, 2015 , ... ... technologies and development solutions for drugs, biologics, consumer health and animal health products, ... Technology, and will lead a new, dedicated global team of drug development and ...
(Date:10/12/2015)... ... October 13, 2015 , ... North American Tool Corporation has been named ... National Meeting in Rosemont, IL on October 4th. , Each year, ... excellence that customers have come to expect from members of IBC’s marketing group. ...
(Date:10/12/2015)... ... October 12, 2015 , ... Amerec , a leader in ... and skin care equipment, will be displaying custom sauna and steam room solutions at ... high-end resorts and spas as customers, SpaEquip is recognized for their ability to assist ...
(Date:10/12/2015)... , ... October 12, 2015 , ... American Family Care ... expand its footprint by opening its 151st medical center. Located at 606A Boll Weevil ... “We’re excited to continue fulfilling our mission of making quality health care accessible and ...
(Date:10/12/2015)... USA (PRWEB) , ... October 12, 2015 , ... ... personal audio products, will present the latest version of Companion Mics, the CM•4 ... audiometry, at the European Union of Hearing Aid Acousticians’ (EUHA) 60th Annual Congress ...
Breaking Medicine News(10 mins):
(Date:10/12/2015)... 2015 ,The  pharma  ADMET ... as they look to implement more-predictive ADMET testing. ... new report by  visiongain . --> ... from pharmaceutical companies as they look to implement ... appear in a new report by  visiongain . ...
(Date:10/12/2015)...  Today, Divurgent is honored to announce Paul Anderson ... CIO, Paul brings 15 years of hands-on experience as a ... today,s CIOs, he is one. The challenges that face today,s ... and his new role with Divurgent allows him to lead ... organization. ...
(Date:10/12/2015)... Beginning October 1, 2015 All HIPAA Covered ... growing practice management system for therapists, psychologists, and psychiatrists ... patient diagnostic codes from the former DSM-4/ICD-9, to the ... --> Therapy Partner has also generated a ... to easily understand the conversion to ICD-10 codes; this ...
Breaking Medicine Technology: